Navigation Links
Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
Date:12/8/2008

EAST BRUNSWICK, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, Presidentof Savient Pharmaceuticals will be presenting at the upcoming 27th Annual J.P. Morgan Healthcare Conference.

The presentation is scheduled to begin on Wednesday, January 14, 2009 at 4:00 p.m. PT. The Conference will be held at the Westin St. Francis Hotel in San Francisco, CAJanuary 11-15, 2009.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007 and the BLA was filed with the FDA in October 2008. Savient has exclusively licensed worldwide rights to the technology related to pegloticase, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- A leading group of oncologists has released updated ... advanced breast cancer. HER2-negative breast tumors include ... HER2 protein, the American Society of Clinical Oncology (ASCO) ... 80 percent of women with advanced breast cancer have ... guideline, our aim is to improve both the length ...
(Date:9/2/2014)... Measuring the levels of sex hormones in patients, blood ... a heart rhythm disorder that is fatal in 95 percent ... the peer-reviewed journal Heart Rhythm , shows that lower ... in men who had a sudden cardiac arrest. Higher levels ... with greater chances of having a sudden cardiac arrest in ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... with products and services such as anti-wrinkle treatments ... frequency-device based treatments, and breast augmentation becoming much ... published by U.S.-based market intelligence firm Transparency Market ... and products will grow to USD 191.7 billion ...
(Date:9/2/2014)... PEACHTREE CITY, GA (PRWEB) September 02, 2014 ... a whole new level with the launch of a luxurious ... pleased to announce that the SEA ISLAND COTTON Socks are ... stronger compression level, giving more people the comfort of natural ... ISLAND COTTON Socks, they are surprised to find socks as ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Alliance Strategies ... and multi-channel email marketing is pleased to announce it ... Firearms & Freedom as well as ... represent more than one million concerned Americans who can ... , “We are honored to continue providing our ...
Breaking Medicine News(10 mins):Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:Study links sex hormone levels in the blood to risk of sudden cardiac arrest 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3
... common problem among women. However statistics show that among people ... with knee joint pain, obese people are in the majority. ... definite about the reasons for the knee pain. //Majority of ... briefly. ,The basic sturcture of knee joint is composed ...
... young as even 3 days old can tell whether someone ... author, doubts that humans have evolved to be sensitive to ... Farroni is a researcher with the Centre for Brain and ... University of London.// ,Farroni, felt that newborns are not ...
... The first major trans-Atlantic telesurgical operation has been carried ... from a patient in eastern France by remotely operating ... for a surgeon to perform an operation on a ... Institute of Telesurgery in Strasbourg say the procedure was ...
... their new study suggested that, along with calcium, protein ... Getting enough calcium is essential for building and maintaining ... men and women who were taking calcium citrate malate ... density increased most in people whose diets contained the ...
... a biomedical engineer at the University of Pittsburgh makes ... your eyes. The prototype device merges the visual outer ... scan of what lies beneath. It creates the effect ... 3D location with the patient, showing blood vessels, muscle ...
... with Alzheimer’s may worsen the symptoms of Parkinson’s ... could improve treatments for these conditions, say US ... up to one-third of Alzheimer’s patients develop Parkinson’s ... ,To research a possible link between ...
Cached Medicine News:Health News:New combined therapy for Knee Joint pain 2Health News:Newborns Know how to make eye contact 2Health News:Calcium and Protein Equals Strong Bones 2Health News:New form of ultrasonic vision 2
(Date:9/2/2014)... , Sept. 2, 2014  XBiotech announced ... study being conducted in the US for its ... Human™ monoclonal antibody therapy, is being evaluated in ... complicated with cachexia. The primary endpoint of the ... treated patients to a control population provided only ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... CANTEL MEDICAL CORP. (NYSE: CMN ) ... per diluted share, on a 24% increase in sales to a ... compares with net income of $4,274,000, or $0.25 per diluted share, ... 2010.  For the nine months ended April 30, 2011, the Company ...
... Pa., June 8, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical ... treat cancer, today announced the appointment of Mr. Jonathan ... and vice president of corporate development. ... of corporate development and finance experience.  He has led ...
Cached Medicine Technology:Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development 2
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
... Solo Lumbar Allografts are ... that maximizes compressive strength and ... permits the use of preferred ... healing. Specially designed instruments facilitate ...
... comprised of two cortical planks of ... cortical planks provide strength for anterior ... a lattice for remodeling, ensuring an ... surface teeth increase the stability of ...
Medicine Products: